Yantai Zhenghai Bio-Tech Co Ltd
Yantai Zhenghai Biotechnology Co., Ltd. engages in the research and development, production, and sales of bioregenerative medical materials in China. The company offers oral repair membranes, absorbable dura mater patches, active biological bones, skin repair membranes, bone repair materials, surgical packing sponges, phosphoric acid etchant, dental pit and fissure sealant, light-curing composite… Read more
Yantai Zhenghai Bio-Tech Co Ltd (300653) - Net Assets
Latest net assets as of September 2025: CN¥874.47 Million CNY
Based on the latest financial reports, Yantai Zhenghai Bio-Tech Co Ltd (300653) has net assets worth CN¥874.47 Million CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥964.85 Million) and total liabilities (CN¥90.38 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥874.47 Million |
| % of Total Assets | 90.63% |
| Annual Growth Rate | N/A |
| 5-Year Change | 37.43% |
| 10-Year Change | 395.41% |
| Growth Volatility | 58.76 |
Yantai Zhenghai Bio-Tech Co Ltd - Net Assets Trend (2012–2024)
This chart illustrates how Yantai Zhenghai Bio-Tech Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Yantai Zhenghai Bio-Tech Co Ltd (2012–2024)
The table below shows the annual net assets of Yantai Zhenghai Bio-Tech Co Ltd from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥888.78 Million | -6.25% |
| 2023-12-31 | CN¥948.07 Million | +9.59% |
| 2022-12-31 | CN¥865.11 Million | +10.17% |
| 2021-12-31 | CN¥785.27 Million | +21.42% |
| 2020-12-31 | CN¥646.72 Million | +9.91% |
| 2019-12-31 | CN¥588.38 Million | +11.23% |
| 2018-12-31 | CN¥529.00 Million | +9.48% |
| 2017-12-31 | CN¥483.18 Million | +111.77% |
| 2016-12-31 | CN¥228.16 Million | +27.18% |
| 2015-12-31 | CN¥179.40 Million | +181.98% |
| 2014-12-31 | CN¥63.62 Million | +116.87% |
| 2013-12-31 | CN¥29.34 Million | +556.19% |
| 2012-12-31 | CN¥-6.43 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Yantai Zhenghai Bio-Tech Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 51646221855.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥490.08 Million | 55.14% |
| Common Stock | CN¥180.00 Million | 20.25% |
| Other Comprehensive Income | CN¥99.20 Million | 11.16% |
| Other Components | CN¥119.50 Million | 13.45% |
| Total Equity | CN¥888.78 Million | 100.00% |
Yantai Zhenghai Bio-Tech Co Ltd Competitors by Market Cap
The table below lists competitors of Yantai Zhenghai Bio-Tech Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PHOENIX N AG
SW:PMN
|
$269.66 Million |
|
Hai An Transport and Stevedoring JSC
VN:HAH
|
$269.71 Million |
|
ATN International Inc
NASDAQ:ATNI
|
$269.75 Million |
|
Shift Up Corporation
KO:462870
|
$269.78 Million |
|
Beibu Gulf Tourism Corp Ltd
SHG:603869
|
$269.65 Million |
|
Broadleaf Co. Ltd
PINK:BRDLF
|
$269.57 Million |
|
Senci Electric Machinery Co Ltd
SHG:603109
|
$269.53 Million |
|
Nanjing Zhongbei Group Co Ltd
SHE:000421
|
$269.49 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Yantai Zhenghai Bio-Tech Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 948,065,365 to 888,784,131, a change of -59,281,234 (-6.3%).
- Net income of 134,639,109 contributed positively to equity growth.
- Dividend payments of 143,999,989 reduced retained earnings.
- Share repurchases of 49,920,352 reduced equity.
- Other comprehensive income increased equity by 99,202,234.
- Other factors decreased equity by 99,202,236.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥134.64 Million | +15.15% |
| Dividends Paid | CN¥144.00 Million | -16.2% |
| Share Repurchases | CN¥49.92 Million | -5.62% |
| Other Comprehensive Income | CN¥99.20 Million | +11.16% |
| Other Changes | CN¥-99.20 Million | -11.16% |
| Total Change | CN¥- | -6.25% |
Book Value vs Market Value Analysis
This analysis compares Yantai Zhenghai Bio-Tech Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.06x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥-0.12 | CN¥20.12 | x |
| 2013-12-31 | CN¥0.55 | CN¥20.12 | x |
| 2014-12-31 | CN¥1.20 | CN¥20.12 | x |
| 2015-12-31 | CN¥1.46 | CN¥20.12 | x |
| 2016-12-31 | CN¥1.69 | CN¥20.12 | x |
| 2017-12-31 | CN¥2.99 | CN¥20.12 | x |
| 2018-12-31 | CN¥2.93 | CN¥20.12 | x |
| 2019-12-31 | CN¥3.25 | CN¥20.12 | x |
| 2020-12-31 | CN¥3.61 | CN¥20.12 | x |
| 2021-12-31 | CN¥4.38 | CN¥20.12 | x |
| 2022-12-31 | CN¥5.97 | CN¥20.12 | x |
| 2023-12-31 | CN¥5.26 | CN¥20.12 | x |
| 2024-12-31 | CN¥4.95 | CN¥20.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Yantai Zhenghai Bio-Tech Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.15%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 37.07%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 1.10x
- Recent ROE (15.15%) is below the historical average (22.61%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 14.36% | 0.65x | 0.00x | CN¥9.16 Million |
| 2013 | 53.75% | 20.38% | 0.99x | 2.65x | CN¥12.83 Million |
| 2014 | 52.91% | 31.96% | 1.28x | 1.29x | CN¥27.30 Million |
| 2015 | 23.69% | 33.16% | 0.64x | 1.12x | CN¥24.55 Million |
| 2016 | 19.93% | 30.19% | 0.58x | 1.14x | CN¥22.65 Million |
| 2017 | 12.76% | 33.74% | 0.34x | 1.10x | CN¥13.35 Million |
| 2018 | 16.22% | 39.81% | 0.37x | 1.10x | CN¥32.92 Million |
| 2019 | 18.25% | 38.38% | 0.39x | 1.22x | CN¥48.55 Million |
| 2020 | 18.30% | 40.35% | 0.36x | 1.25x | CN¥53.66 Million |
| 2021 | 21.46% | 42.12% | 0.43x | 1.18x | CN¥90.03 Million |
| 2022 | 21.44% | 42.80% | 0.44x | 1.14x | CN¥98.93 Million |
| 2023 | 20.14% | 46.16% | 0.39x | 1.11x | CN¥96.15 Million |
| 2024 | 15.15% | 37.07% | 0.37x | 1.10x | CN¥45.76 Million |
Industry Comparison
This section compares Yantai Zhenghai Bio-Tech Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Yantai Zhenghai Bio-Tech Co Ltd (300653) | CN¥874.47 Million | 0.00% | 0.10x | $269.66 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |